by alexcastillo | Dec 24, 2020 | MAT Resources
The Medical Advisory Team updates its recommendation regarding out-of-hospital infusion services to manage the risk of infusion reactions in patients treated with intravenous therapies for COVID-19 infection: Personnel providing infusion therapy for COVID-19 should...
by alexcastillo | Dec 21, 2020 | MAT Resources
The Medical Advisory Team (MAT) Vaccine Safety and Efficacy Workgroup has reviewed the relevant documents related to the Moderna mRNA-1273 vaccine as provided by the manufacturer, the U.S. Food and Drug Administration (FDA), and the U.S. Centers for Disease Control...
by alexcastillo | Dec 18, 2020 | MAT Resources
The Medical Advisory Team (MAT) Vaccine Safety and Efficacy Work group has revised its recommendation to include additional guidance on the management of vaccine supply, including the full use of multi-dose vial contents that may contain more than 5 doses per vial....
by alexcastillo | Dec 16, 2020 | MAT Resources
Baricitinib should be consider for use by healthcare providers, in combination with remdesivir (Veklury), to treat suspected or laboratory confirmed COVID-19 in hospitalized adults and pediatric patients 2 years of age or older requiring supplemental oxygen, invasive...
by alexcastillo | Nov 30, 2020 | MAT Resources
Casirivimab and imdevimab (REGN-COV2), which is produced by Regeneron Pharmaceuticals, should be used for outpatient treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 88 pounds) as soon as possible...
by alexcastillo | Nov 18, 2020 | MAT Resources
This guidance is intended to assist with the outpatient management of patients with respiratory compromise who are clinically stable with moderate COVID-19 symptoms but who, if monitored on an outpatient basis, do not require hospitalization due to severity of...
